These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 29162675)

  • 21. Health care practitioners' experience-based opinions on providing care after a positive newborn screen for Pompe disease.
    Davids L; Sun Y; Moore RH; Lisi E; Wittenauer A; Wilcox WR; Ali N
    Mol Genet Metab; 2021; 134(1-2):20-28. PubMed ID: 34602357
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of enzyme replacement therapy in late onset Pompe disease: open pilot study of 48 weeks follow-up.
    Park JS; Kim HG; Shin JH; Choi YC; Kim DS
    Neurol Sci; 2015 Apr; 36(4):599-605. PubMed ID: 25388776
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program.
    Chien YH; Chiang SC; Zhang XK; Keutzer J; Lee NC; Huang AC; Chen CA; Wu MH; Huang PH; Tsai FJ; Chen YT; Hwu WL
    Pediatrics; 2008 Jul; 122(1):e39-45. PubMed ID: 18519449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond.
    Kishnani PS; Beckemeyer AA
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():114-24. PubMed ID: 25345093
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 36-Months follow-up assessment after cessation and resuming of enzyme replacement therapy in late onset Pompe disease: data from the Swiss Pompe Registry.
    Scheidegger O; Leupold D; Sauter R; Findling O; Rösler KM; Hundsberger T
    J Neurol; 2018 Dec; 265(12):2783-2788. PubMed ID: 30232608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enzyme replacement therapy with alglucosidase alfa in Pompe disease: Clinical experience with rate escalation.
    Desai AK; Walters CK; Cope HL; Kazi ZB; DeArmey SM; Kishnani PS
    Mol Genet Metab; 2018 Feb; 123(2):92-96. PubMed ID: 29289479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment.
    Montagnese F; Barca E; Musumeci O; Mondello S; Migliorato A; Ciranni A; Rodolico C; De Filippi P; Danesino C; Toscano A
    J Neurol; 2015; 262(4):968-78. PubMed ID: 25673129
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disparities in late and lost: Pediatricians' role in following Pompe disease identified by newborn screening.
    Pillai NR; Fabie NAV; Kaye TV; Rosendahl SD; Ahmed A; Hietala AD; Jorgenson AB; Lanpher BC; Whitley CB
    Mol Genet Metab; 2023; 140(1-2):107633. PubMed ID: 37414610
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early higher dosage of alglucosidase alpha in classic Pompe disease.
    Spada M; Pagliardini V; Ricci F; Biamino E; Mongini T; Porta F
    J Pediatr Endocrinol Metab; 2018 Dec; 31(12):1343-1347. PubMed ID: 30433875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current status of newborn screening for Pompe disease in Japan.
    Sawada T; Kido J; Sugawara K; Momosaki K; Yoshida S; Kojima-Ishii K; Inoue T; Matsumoto S; Endo F; Ohga S; Hirose S; Nakamura K
    Orphanet J Rare Dis; 2021 Dec; 16(1):516. PubMed ID: 34922579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early clinical phenotype of late onset Pompe disease: Lessons learned from newborn screening.
    Huggins E; Holland M; Case LE; Blount J; Landstrom AP; Jones HN; Kishnani PS
    Mol Genet Metab; 2022 Mar; 135(3):179-185. PubMed ID: 35123877
    [TBL] [Abstract][Full Text] [Related]  

  • 32. White matter lesions in treated late onset Pompe disease are not different to matched controls.
    Schneider I; Hensel O; Zierz S
    Mol Genet Metab; 2019 Jun; 127(2):128-131. PubMed ID: 31153821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Start, switch and stop (triple-S) criteria for enzyme replacement therapy of late-onset Pompe disease: European Pompe Consortium recommendation update 2024.
    Schoser B; van der Beek NAME; Broomfield A; Brusse E; Diaz-Manera J; Hahn A; Hundsberger T; Kornblum C; Kruijshaar M; Laforet P; Mengel E; Mongini T; Orlikowski D; Parenti G; Pijnappel WWMP; Roberts M; Scherer T; Toscano A; Vissing J; van den Hout JMP; van Doorn PA; Wenninger S; van der Ploeg AT
    Eur J Neurol; 2024 Sep; 31(9):e16383. PubMed ID: 38873957
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic factors for the late onset Pompe disease with enzyme replacement therapy: from our experience of 4 cases including an autopsy case.
    Kobayashi H; Shimada Y; Ikegami M; Kawai T; Sakurai K; Urashima T; Ijima M; Fujiwara M; Kaneshiro E; Ohashi T; Eto Y; Ishigaki K; Osawa M; Kyosen SO; Ida H
    Mol Genet Metab; 2010 May; 100(1):14-9. PubMed ID: 20202878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term enzyme-replacement therapy (ERT) with alglucosidase alfa: Evolution of two siblings with juvenile late-onset Pompe disease.
    Rafael Bretón Martínez J; Martínez AC
    J Neurol Sci; 2015 Nov; 358(1-2):459-60. PubMed ID: 26279333
    [No Abstract]   [Full Text] [Related]  

  • 36. Description of clinical and genetic features of 122 patients included in the Spanish Pompe registry.
    Martinez-Marin RJ; Reyes-Leiva D; Nascimento A; Muelas N; Dominguez-González C; Paradas C; Olivé M; García-Romero M; Pascual-Pascual SI; Grau JM; Barba-Romero MA; Gomez-Caravaca MT; de Las Heras J; Casquero P; Mendoza MD; de León JC; Gutierrez A; Morís G; Blanco-Lago R; Ramos-Fransi A; Pintós G; García-Antelo MJ; Rabasa M; Morgado Y; Usón M; Miralles FJ; Bárcena-Llona JE; Gómez-Belda AB; Pedraza-Hueso MI; Hortelano M; Colomé A; Garcia-Martin G; Lopez de Munain A; Jericó I; Galán-Dávila L; Pardo J; Salgueiro-Origlia G; Alonso-Pérez J; Pla-Junca F; Schiava M; Segovia-Simón S; Díaz-Manera J
    Neuromuscul Disord; 2024 Jan; 34():1-8. PubMed ID: 38087756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enzyme replacement therapy with alglucosidase alfa in a late-onset Pompe disease patient during pregnancy.
    Oliveira Santos M; Evangelista T; Conceição I
    Neuromuscul Disord; 2018 Nov; 28(11):965-968. PubMed ID: 30314719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Health and economic outcomes of newborn screening for infantile-onset Pompe disease.
    Richardson JS; Kemper AR; Grosse SD; Lam WKK; Rose AM; Ahmad A; Gebremariam A; Prosser LA
    Genet Med; 2021 Apr; 23(4):758-766. PubMed ID: 33281187
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clinical guidelines for infantile-onset Pompe disease].
    Pascual-Pascual SI; Nascimento A; Fernandez-Llamazares CM; Medrano-Lopez C; Villalobos-Pinto E; Martinez-Moreno M; Ley M; Manrique-Rodriguez S; Blasco-Alonso J
    Rev Neurol; 2016 Sep; 63(6):269-79. PubMed ID: 27600742
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Close monitoring of initial enzyme replacement therapy in a patient with childhood-onset Pompe disease.
    Ishigaki K; Murakami T; Nakanishi T; Oda E; Sato T; Osawa M
    Brain Dev; 2012 Feb; 34(2):98-102. PubMed ID: 21676566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.